Shares of Capricor Therapeutics (CAPR) touched a 52-week high of $21.21 in early trading today, as anticipation builds for the upcoming release of long-term data from the company's ongoing HOPE-2 Open Label Extension Study.
The HOPE-2 open-label extension trial is a phase II study evaluating the company's lead drug candidate, Deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.